Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,543
  • Shares Outstanding, K 21,333
  • Annual Sales, $ 2,390 K
  • Annual Income, $ -15,970 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.16
  • Price/Sales 6.15
  • Price/Cash Flow N/A
  • Price/Book 1.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.06
  • Most Recent Earnings $-0.39 on 11/04/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.42
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6200 +9.95%
on 11/11/25
0.9399 -27.47%
on 10/27/25
-0.1183 (-14.79%)
since 10/14/25
3-Month
0.6200 +9.95%
on 11/11/25
0.9900 -31.14%
on 10/09/25
-0.0735 (-9.73%)
since 08/14/25
52-Week
0.6200 +9.95%
on 11/11/25
2.2400 -69.57%
on 01/06/25
-1.3983 (-67.23%)
since 11/14/24

Most Recent Stories

More News
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging No approved...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron Appoints Dr. George Paletta to Board

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Longeveron...

LGVN : 0.6817 (-1.17%)
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s disease Alzheimer’s disease development program with positive data in successful...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Announces Key Leadership Updates

Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric...

LGVN : 0.6817 (-1.17%)
LGVNR : 0.0005 (-37.50%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 0.7443
2nd Resistance Point 0.7272
1st Resistance Point 0.7044
Last Price 0.6817
1st Support Level 0.6645
2nd Support Level 0.6474
3rd Support Level 0.6246

See More

52-Week High 2.2400
Fibonacci 61.8% 1.6212
Fibonacci 50% 1.4300
Fibonacci 38.2% 1.2388
Last Price 0.6817
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar